Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Additional criteria check may apply for qualification:~* Glycated hemoglobin(HbA1c) of ≥6.5% and ≤12.0%~* eGFR of ≥30 mL/min/1.73m2 and \<90 mL/min/1.73m2~* The median UACR of the first morning void urine samples is ≥300 mg/g Cr and ≤5000 mg/g Cr~* Patients who are taking on angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)~* Patients who are under dietary management and taking therapeutic exercise for diabetes~Exclusion Criteria:~Additional criteria check may apply for qualification:~* Type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes~* A diagnosis of non-diabetic renal disease~* Hereditary glucose-galactose malabsorption or primary renal glucosuria~* Class IV heart failure symptoms according to New York Heart Association (NYHA) functional classification~* Severe hepatic disorder or severe renal disorder~* Blood potassium level \>5.5 mmoL/L~* Stable blood pressure (diastolic blood pressure (DBP) ≥100mmHg or systolic blood pressure (SBP) ≥180mmHg)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).